Loading the company…
Loading the company…
㈜엠에스바이오
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-10-11 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Gyeonggi, founded in 2015. Industry: Medical & Precision Devices. Revenue for 2025 was ₩23.8bn. It has 57 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2024-12-03 · latest registration 2025-07-07 · newest first
본 발명은 에틸렌 옥사이드 가스에 처리된 양막을 포함하는 양막 드레싱 및 이의 제조방법에 관한 것이다. 본 발명의 양막 드레싱은 에틸렌 옥사이드 가스에 양막을 반응시켜 양막 드레싱의 투명도, 및 구조적 안정성을 개선한 효과가 있다.
본 발명은 안구 표면 질환의 치료에 사용될 수 있는 양막링 및 이의 제조방법에 관한 것으로, 본 발명에 따른 양막링은 각막의 창상 치유를 목적으로 한 양막이식분야에서,이식된 양막의 봉합이 불필요하여 봉합에 따른 합병증을 최소화하고, 렌즈 형태를 가져 외래에서 간편하게 사용할 수 있다. 나아가, 별도의 O-링 없이 렌즈 형태로 양막의 고정이 가능하고, 지지체 표면에 폴리비닐알콜 하이드로겔 코팅층이 위치하여 안구 삽입시 이물감과 불편함을 크게 감소시킬 수 있으며, 안구 중심에서 양막링이 이탈하지 않고 위치할 수 있다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 2 of 2 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 18.0 | 23.8 |
| Cost of sales | (6.3) | (8.0) |
| Gross profit (loss) | 11.7 | 15.8 |
| Selling, general and administrative expenses | (5.7) | (7.2) |
| Operating income (loss) | 6.0 | 8.6 |
| Non-operating income | 0.2 | 0.3 |
| Other gains | 0.1 | 0.0 |
| Finance income | 0.1 | 0.3 |
| Non-operating expenses | (0.0) | (0.2) |
| Other losses | (0.0) | (0.0) |
| Finance costs | (0.0) | (0.2) |
| Profit (loss) before tax | 6.1 | 8.6 |
| Income tax expense | 0.8 | 1.3 |
| Net income (loss) | 5.3 | 7.3 |
Revenue ₩23.8bn, up 32.3% YoY.
Operating margin 36.0% (prior 33.3%).
Net income ₩7.3bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06